Amanote Research
Register
Sign In
Reduction of Bleomycin Induced Lung Fibrosis by Candesartan Cilexetil, an Angiotensin II Type 1 Receptor Antagonist
Thorax
- United Kingdom
doi 10.1136/thx.2003.000893
Full Text
Open PDF
Abstract
Available in
full text
Categories
Pulmonary
Respiratory Medicine
Date
January 1, 2004
Authors
M Otsuka
Publisher
BMJ
Related search
Population Pharmacokinetics of New Angiotensin II Receptor Antagonists, Candesartan Cilexetil (TCV-116).
Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury
Frontiers in Physiology
Physiology
Regulation of Angiotensin II Type 1 Receptor mRNA and Protein in Angiotensin II Induced Hypertension
Hypertension
Internal Medicine
Renal Hemodynamic and Hormonal Responses to the Angiotensin II Antagonist Candesartan
Hypertension
Internal Medicine
Angiotensin Receptor Blocker Protection Against Podocyte-Induced Sclerosis Is Podocyte Angiotensin II Type 1 Receptor-Independent
Hypertension
Internal Medicine
Biorelevant Dissolution of Candesartan Cilexetil
ADMET and DMPK
Pharmacology
Health
Medicine
Toxicology
Chemistry
Pharmaceutics
In Vitro Pharmacological Properties of KRH-594, a Novel Angiotensin II Type 1 Receptor Antagonist.
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Negative Regulation of VEGF-Induced Vascular Leakage by Blockade of Angiotensin II Type 1 Receptor
Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular Medicine
Cardiology
Increased Expression of Angiotensin Converting Enzyme 2 in Conjunction With Reduction of Neointima by Angiotensin II Type 1 Receptor Blockade
Hypertension Research
Internal Medicine
Cardiovascular Medicine
Physiology
Cardiology
